Table 1.

Summary of Existing Data on COVID-19 Vaccines in Patients With Liver Disease.

Name of vaccine	Type of vaccine	Data in general population	Data in patients with liver disease
Pfizer-BioNTech vaccine (BNT 162b2)7	mRNA vaccine	Efficacy: 95% compared to placebo Adverse events: Total AR = 26.7% Most common AR = pain at the injection site, fatigue and headache Serious AR = 0.6% Including shoulder injury related to vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia and right leg paraesthesia	214 patients with mild liver disease and 3 patients with moderate and severe liver disease included Liver transplant recipients and autoimmune liver disease on steroids excluded Results not reported separately
Moderna vaccine (mRNA-1273)8	mRNA vaccine	Efficacy: 94.1% compared to placebo Local AR: 84.2%–88.6% Most common AR: local pain Systemic AR: 54.9–79.4% Most common: fatigue, myalgia, arthralgia Serious AR-1%	196 patients included Patients on immunosuppression excluded Results not reported separately
ChAdOx1 nCoV-19 vaccine (AZD1222)11	Adenovector virus vaccine	Efficacy: 70.4% Serious AR: 0.7%	The study included four different trials conducted in different centres Excluded liver function tests abnormalities, Australian antigen positivity, chronic liver disease, alcohol abuse, patients on immunosuppression. Liver function abnormality: 2 patients Results not reported separately for patients with liver disease
BBV152 vaccine14	Whole virion inactivated vaccine	Seroconversion achieved in 92.9–98.3%	Phase 2 data were published Local AR: 3.7–4.7% Systemic AR: 5.8–7.4% Patients with chronic liver disease and those on immunosuppression were excluded